MethylphenidatePriapism following off label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1636卷 / 1期

关键词：

D O I：

10.1007/s40278-017-25774-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：214 / 214

相关论文

共 50 条

[41] PembrolizumabOral mucositis following off label use: case report
Reactions Weekly, 2018, 1706 (1) : 407 - 407
[42] BevacizumabMyocardial infarction following off label use: case report
Reactions Weekly, 2018, 1701 (1) : 58 - 58
[43] TocilizumabNeutropenia following off-label use: case report
Reactions Weekly, 2021, 1853 (1) : 446 - 446
[44] RituximabAllergic reaction following off label use: case report
Reactions Weekly, 2019, 1783 (1) : 212 - 212
[45] Lopinavir/ritonavirDiarrhoea following off label use: case report
Reactions Weekly, 2021, 1863 (1) : 212 - 212
[46] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2019, 1744 (1) : 111 - 111
[47] GlibenclamideHypoglycaemia following off-label use: case report
Reactions Weekly, 2021, 1857 (1) : 162 - 162
[48] TocilizumabAnastomotic leakage following off label use: case report
Reactions Weekly, 2021, 1879 (1) : 339 - 339
[49] FampridineDizziness and nausea following off label use: case report
Reactions Weekly, 2019, 1775 (1) : 207 - 207
[50] SunitinibCardiomyopathy following off-label use: case report
Reactions Weekly, 2023, 1971 (1) : 240 - 240

← 1 2 3 4 5 →